Home > Oncology > ASCO 2019 > Kidney Cancer > Classification of metastatic renal cell carcinoma patients in immunotherapy era and positive responses for sarcomatoid tumours

Classification of metastatic renal cell carcinoma patients in immunotherapy era and positive responses for sarcomatoid tumours

Presented By
Prof. Bernhard Escudier, Gustave Roussy Cancer Campus, Paris, France
Conference
ASCO 2019
Trial
CheckMate 214
Medical writer: Dr. Rachel H. Giles Prof. Bernhard Escudier (Gustave Roussy Cancer Campus, Paris, France) presented a post-hoc analysis of CheckMate 214, concluding that the IMDC prognostic criteria, based on anti-VEGF treatment outcomes, may not be as relevant for immunotherapy treatment outcomes in metastatic renal cell carcinoma [1]. Prof. D. McDermott (Dana-Farber, Harvard Cancer Centre, USA) presented a subgroup analysis demonstrating that the ipilimumab + nivolumab arm provided improved efficacy and prolonged survival vs sunitinib, with consistent safety, in previously untreated, intermediate/poor-risk, advanced clear-cell RCC with sarcomatoid features [2]. The randomised controlled trial CheckMate 214 (ipilimumab + nivolumab vs sunitinib in 1st line metastatic renal cell carcinoma) demonstrated a complete response rate of 16% in patients with intermediate- and poor-risk features whose tumour tested positive for PD-L1. The key take-home message was th...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on